Owen Mumford Announces Verified Science-based Targets & Plans for Net zero

Owen Mumford, a global leader in the design, manufacture and advancement of medical devices, has announced its emissions reduction targets through the Science Based Targets initiative (SBTi). The company has set a target to achieve net zero by 2045 (to mirror the UK NHS target) in alignment with the recommendations of the 2015 Paris Agreement.

Using science-based targets, companies can determine how much and how quickly they need to reduce their greenhouse gas (GHG) emissions to prevent the worst effects of climate change. The Science Based Targets initiative (SBTi) sets science-based emissions reduction targets in line with climate science, supporting companies as they mobilise ambitious climate action efforts in the private sector. Over 2,000 companies worldwide have already set their targets.

As part of its sustainability action plan, the company has joined the Business Ambition for 1.5°c commitment and is one of the first 1000 global businesses to sign up. Launched in 2019, the initiative asks members to pledge to achieve net zero emissions by the latest 2050 following the United Nations Intergovernmental Panel on Climate Change (IPCC) warning that an increase of 1.5°c in global temperature will have catastrophic effects.

By joining the commitment, Owen Mumford also joins the Race to Zero movement, a collaborative effort of leaders across the globe supporting efforts to achieve zero carbon recovery. Owen Mumford recently became one of the first medical device manufacturers in the world to achieve B Corp certification following the establishment of its sustainability programme in 2014 and formal commitment to the United Nation’s Sustainable Development Goals (SDGs). To formalise the pledge to reduce the environmental impact of its operations, Owen Mumford has now set a science-based target, with its base year as 2015. The company will establish a pathway in 2022, including milestones to mark the achievement of goals and measure its success. The focus will be on Scope 3 emissions, which covers factors such as purchased goods and services, business travel and waste disposal.

Jarl Severn, Ceo At Owen Mumford
Jarl Severn, Ceo At Owen Mumford

Jarl Severn, CEO at Owen Mumford said: “Owen Mumford has been an innovator of medical devices for decades, and we understand the importance of leading by example when it comes to the environment and our impact as a business. Setting a science-based target with the SBTi will hold us accountable and help us to reach our net zero target for 2045. We hope this commitment will inspire other businesses to implement their own sustainability targets and work towards the goal of a carbon neutral future.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy